+

WO2008109005A3 - Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers - Google Patents

Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers Download PDF

Info

Publication number
WO2008109005A3
WO2008109005A3 PCT/US2008/002747 US2008002747W WO2008109005A3 WO 2008109005 A3 WO2008109005 A3 WO 2008109005A3 US 2008002747 W US2008002747 W US 2008002747W WO 2008109005 A3 WO2008109005 A3 WO 2008109005A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotoxins
protein
synthesis
cell cancers
treatment
Prior art date
Application number
PCT/US2008/002747
Other languages
French (fr)
Other versions
WO2008109005A2 (en
Inventor
Ira H Pastan
Alan Wayne
Yachna Ahuja
Laiman Xiang
Original Assignee
Us Gov Health & Human Serv
Ira H Pastan
Alan Wayne
Yachna Ahuja
Laiman Xiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Ira H Pastan, Alan Wayne, Yachna Ahuja, Laiman Xiang filed Critical Us Gov Health & Human Serv
Publication of WO2008109005A2 publication Critical patent/WO2008109005A2/en
Publication of WO2008109005A3 publication Critical patent/WO2008109005A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the discovery that contacting CD22+-cancer cells with both an anti-CD22 immunotoxin whose toxin portion is a protein synthesis inhibitor and a chemotherapeutic agent that inhibits protein synthesis results in greater cytotoxicity to the cells than would be expected. This synergistic effect can be exploited to inhibit the growth of CD22+ B cell cancers.
PCT/US2008/002747 2007-03-02 2008-02-28 Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers WO2008109005A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89281907P 2007-03-02 2007-03-02
US60/892,819 2007-03-02
US89359607P 2007-03-07 2007-03-07
US60/893,596 2007-03-07

Publications (2)

Publication Number Publication Date
WO2008109005A2 WO2008109005A2 (en) 2008-09-12
WO2008109005A3 true WO2008109005A3 (en) 2009-01-08

Family

ID=39595606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002747 WO2008109005A2 (en) 2007-03-02 2008-02-28 Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers

Country Status (1)

Country Link
WO (1) WO2008109005A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027135A2 (en) * 2001-09-26 2003-04-03 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
WO2003045429A2 (en) * 2001-11-28 2003-06-05 Novartis Ag Anti-t cell immunotoxin fusion protein and its therapeutic use
WO2005052006A2 (en) * 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
WO2007016150A2 (en) * 2005-07-29 2007-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Mutated pseudomonas exotoxins with reduced antigenicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027135A2 (en) * 2001-09-26 2003-04-03 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
WO2003045429A2 (en) * 2001-11-28 2003-06-05 Novartis Ag Anti-t cell immunotoxin fusion protein and its therapeutic use
WO2005052006A2 (en) * 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
WO2007016150A2 (en) * 2005-07-29 2007-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Mutated pseudomonas exotoxins with reduced antigenicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DECKER THOMAS ET AL: "Induction of caspase-dependent programmed cell death in B-CLL cells by recombinant anti-CD22 immunotoxins", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 103, no. 7, 1 April 2004 (2004-04-01), pages 2718 - 2726, XP002499412, ISSN: 0006-4971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Also Published As

Publication number Publication date
WO2008109005A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
GB2437875B (en) Skin care composition comprising L-carnosine and N-acetylcysteine
CA125062S (en) Bottle
SG129355A1 (en) Method and structure to prevent silicide strappingof source/drain to body in semiconductor devices with source/drain stressor
AU317602S (en) Band
TWI373110B (en) Semiconductor die with through-hole via on saw streets and through-hole via in active area of die
EA019744B9 (en) Isothiazolyloxyphenyl amidines and use thereof for combating fungi and seed material treated with isothiazolyloxyphenyl amidines
AU313858S (en) Media device
MY160041A (en) Compositions and methods for treating parasitic infections
MX2010003977A (en) Combination therapy with antibody-drug conjugates.
AU314223S (en) Appendage wrap
AU319646S (en) Rail
AU317011S (en) Tractor
AU313473S (en) Appendage wrap
GT200900008A (en) NOVEDOUS AMINOPIRIDINE DERIVATIVES THAT HAVE SELECTIVE INHIBITORY ACTION ON AURORA A
EP2091540A4 (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
PL2465493T3 (en) Topical compositions for the prevention and treatment of irritation of mucous cells
EP2164490A4 (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
AU308176S (en) Tractor
WO2008092580A3 (en) Synergistic fungicidal combinations comprising formononetin
AU314978S (en) Equine back wrap
WO2007124382A3 (en) Inhaled imipenem
IL196603A (en) Oroate derivatives for use in the treating tumors and hematopoietic disorders to reduce chemotherapy-induced side effects
WO2008109005A3 (en) Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers
AU312545S (en) Scissors
UA104274C2 (en) Hydrosulphuric derivatives of non-steroidal anti-inflammatory drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726308

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08726308

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载